Navigation Links
Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Date:8/1/2008

SAN DIEGO, Aug. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Bank of America 2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at 8:45 a.m. EDT (5:45 a.m. PDT). The conference is being held at the Southampton Inn in Long Island, New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through August 22, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develo
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
8. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... 2014 at 2pm EST (11am PST), “Natural Language ... topic focuses on how technology can turn raw, ... critical decisions for government agencies. The online webinar ... Data has become an obstacle for government entities. ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations ... events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... Virginia Cox re-joins 3D after more than two years ... Affairs at the U.S. Food and Drug Administration (FDA). As ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... products to serve the wound care market. , ... late 2012, Alliqua was restructured with a seasoned ... new strategy to become a leading provider of ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 20, 2011 , Daval International ... randomised, placebo-controlled, double blind Phase II,Study, Treating Patients ... Sclerosis (SPMS). Standard clinical,measures and assessment scores recorded ... biomarkers will be used to investigate safety,efficacy and ...
... WAYNE, Pa. and PETACH TIKVA, Israel, July 20, 2011 ... developing Detect-Ready® tests designed to increase the speed and ... diagnostics distributor Eldan, a part on the Neopharm Group, ... agreement for distribution of MDI,s Detect-Ready MRSA Panel in ...
... Institute have developed a new method to harvest energy ... creation of self-powered microsensors for more accurate and cost-efficient ... the researchers investigated how the flow of water over ... amounts of electricity. The research team demonstrated the creation ...
Cached Biology Technology:Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3Molecular Detection Inc. and Eldan Electronic Instruments Announce Distribution Agreement for Detect-Ready® MRSA Panel in Israel 2Molecular Detection Inc. and Eldan Electronic Instruments Announce Distribution Agreement for Detect-Ready® MRSA Panel in Israel 3Molecular Detection Inc. and Eldan Electronic Instruments Announce Distribution Agreement for Detect-Ready® MRSA Panel in Israel 4New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3
(Date:3/6/2014)... - Crop yields in the fragile semi-arid areas of ... decline in soil fertility resulting from mono-cropping, lack of ... Crops Research Institute for the Semi-Arid Tropics (ICRISAT), University ... precision farming technique called "microdosing," its effect on food ... low cost to farmers. , "Microdosing involves applying a ...
(Date:3/6/2014)... Elsevier, a world-leading provider of scientific, technical, and ... announce that they have entered into a publishing ... its official journal, Journal of the Energy ... Energy Institute , a peer-reviewed quarterly publication first ... researchers and practitioners across the globe engaged in ...
(Date:3/6/2014)... March 3, 2014, Ohr Pharmaceutical (NasdaqCM: OHRP), a pharmaceutical ... large unmet medical needs, and leading global cancer research ... establishment of DepYmed Inc., a new joint venture to ... new joint venture will be a private entity, initially ... Laboratory. The two partners will seek funding and ...
Breaking Biology News(10 mins):Fertilizer in small doses yields higher returns for less money 2Elsevier and Energy Institute work together to publish Journal of the Energy Institute 2Ohr Pharmaceutical and CSHL joint venture to develop trodusquemine, related analogs 2
... the development of a new type of wound dressing ... hospitals, a problem that leads to thousands of deaths ... coating - which can be chemically bonded to gauze ... kills the two most common and harmful types of ...
... save the 50,000 people a year in poor countries killed ... 100 per cent effective. , The vaccine, developed by a ... called Taenia solium. The adult form, caught from eating undercooked ... the host. , This can be debilitating. But far worse ...
... new organs requires a working knowledge of how cells ... an MBL researcher visiting from the University of Barcelona, ... red beard sea sponge, an Atlantic species that grows ... Florida. , , The red beard sponge (Microciona ...
Cached Biology News:UF researchers kill resistant bugs one bandage at a time 2UF researchers kill resistant bugs one bandage at a time 3A vaccine to kill tapeworm 2Simple sea sponge helps scientists understand tissue rejection 2
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
KAI 1 (G-2)...
... Stem Cell (hESC) Starter Kit brings together many ... culturing hESCs as soon as possible. This set ... training courses around the world, including those supported ... been extensively tested using GIBCO's quality process and ...
Biology Products: